Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611824 | 0.86 | HSD11B1 (0.43) | HSD11B1KMT2AMEN1RAB9AKDM2B | |
| SCHEMBL7607410 | 0.84 | KDM4E (0.44) | HSD11B1KMT2AMEN1GAA | |
| SCHEMBL7604377 | 0.83 | OXTR (0.42) | KMT2AMEN1RAB9AHCRTR1HCRTR2 | |
| SCHEMBL7610040 | 0.79 | OXTR (0.42) | KMT2AMEN1RAB9AKDM2BHCRTR1 | |
| SCHEMBL7604509 | 0.78 | SRD5A1 (0.44) | HSD11B1KMT2AMEN1RAB9AKDM2B | |
| SCHEMBL7607815 | 0.77 | HSD11B1 (0.43) | HSD11B1KMT2AMEN1RAB9AKDM2B | |
| SCHEMBL7612715 | 0.73 | HSD11B1 (0.38) | HSD11B1KMT2AMEN1HTTTSHR | |
| SCHEMBL8010007 | 0.69 | KDM2B (0.41) | HSD11B1KMT2AMEN1RAB9AKDM2B | |
| SCHEMBL6671363 | 0.69 | KDM4E (0.47) | KMT2AMEN1GAA | |
| SCHEMBL7605080 | 0.68 | KCNA5 (0.43) | KMT2AMEN1RAB9ANPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6500819-B2 | HAS AN EXCELLENT ANXIOLYTIC EFFECT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| EP-0790237-B1 | BICYCLOLACTAM COMPOUNDS, USE OF THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2002-09-18 | — | — | EP | disclosed |
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICAL COMPANY LIMITED | 2002-07-25 | — | — | US | disclosed |
| US-6355668-B1 | ANXIOLYTIC AGENTS; SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6303623-B1 | TREATING ANXIETY IN A PATIENT IN NEED OF SUCH TREATMENT, COMPRISING ADMINISTERING BICYCLOLACTAM COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6159987-A | Bicyclolactam compounds, use thereof and intermediates for preparing thereof | TAIHO PHARMACEUTICALS, CO. (JP) | 2000-12-12 | — | — | US | disclosed |
| US-6004975-A | ANXIOLYTIC AGENTS WITH SIDE EFFECT REDUCTION | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0790237-A1 | BICYCLOLACTAM COMPOUNDS, USE OF THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE SAME | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099048-A1 | Bicycloloactam compounds, use thereof and intermediates for preparing thereof | CYP11B1, GABRA6, CYP11B2 | HSD11B1 265/4885KMT2A 1683/4885MEN1 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.